Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

This project is an AI-powered intelligent discovery tool designed to help users understand legacy application functionalities. It allows users to upload legacy code repositories via GitHub links, ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

With agentic AI, the database must evolve from a passive ledger to an active reasoning engine that informs, guides, and ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $563 from $565 and keeps a Buy rating on the shares. The firm, which expects steady growth for the cystic fibrosis franchise in ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A former executive at Microsoft ...

Abstract: Graph Contrastive Learning (GCL) has emerged as the foremost approach for self-supervised learning on graph-structured data. GCL reduces reliance on labeled data by learning robust ...